background


Product Information:

GSK-461364

GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM.

Cat. No.: EX-A1728    Purity: >98%
GSK-461364
For research only, Do not use for Human!

SizeUnit Price (US$)StockQuantityOrder
100mg450In-stock
250mg700In-stock
500mg900In-stock
1g1450In-stock
5g4850In-stock


SynonymsGSK461364A
CAS No.929095-18-1
Purity>98%
FormulaC27H28F3N5O2S
Mol Weight543.604
Appearancewhite to grey solid powder
SolubilitySoluble in DMSO
Shelf Life>2 years if stored properly
StoragePowder -20℃ 2 years; In solvent -20℃ 1 month;
ShippingShipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
 
 
Reference:  

[1]. Olmos D, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30.

[2]. Chou YS, et al. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel. Int J Oncol. 2016 Mar;48(3):1187-94.

[3]. Degenhardt Y, et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther. 2010 Jul;9(7):2079-89

[4]. Gilmartin AG, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 2009 Sep 1;69(17):6969-77.

CoACoA of GSK-461364
Smiles:C[C@@H](OC1=C(SC(=C1)N1C=NC2=C1C=C(CN1CCN(C)CC1)C=C2)C(N)=O)C1=CC=CC=C1C(F)(F)F

KEYWORDS: buy GSK-461364 | GSK-461364 supplier | purchase | cost | manufacturer | order | distributor | buy 929095-18-1 | 929095-18-1 supplier